{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:22Z","timestamp":1784930722224,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104848","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:32:13Z","timestamp":1782145933000},"page":"104848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-3868","authenticated-orcid":false,"given":"Chiara","family":"Molinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Delucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Soldato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Antonj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Nader-Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6168-8211","authenticated-orcid":false,"given":"Francesca","family":"Pitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Boncore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Fregatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.breast.2026.104848_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104848_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104848_bib3","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104848_bib4","doi-asserted-by":"crossref","unstructured":"Guven DC, Sahin TK. The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer Res Treat. Published online January 19, 2024. doi:10.1007\/s10549-023-07226-1..","DOI":"10.1007\/s10549-023-07226-1"},{"issue":"4","key":"10.1016\/j.breast.2026.104848_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104848_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"10384","key":"10.1016\/j.breast.2026.104848_bib7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2026.104848_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(22)00632-5","article-title":"Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial","volume":"23","author":"Del Mastro","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104848_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ijc.32789","article-title":"Dose\u2010dense adjuvant chemotherapy in HER2\u2010positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial","volume":"147","author":"Lambertini","year":"2020","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104848_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41416-022-01846-y","article-title":"Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic cooperative oncology group phase III HE10\/05 trial","volume":"127","author":"Zagouri","year":"2022","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104848_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cncr.32653","article-title":"Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: results from the phase 3 PANTHER trial","volume":"126","author":"Papakonstantinou","year":"2020","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.breast.2026.104848_bib12","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10179","key":"10.1016\/j.breast.2026.104848_bib13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.breast.2026.104848_bib14","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41416-020-0816-8","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the phase 3 mammella InterGruppo (MIG)-1 study","volume":"122","author":"Blondeaux","year":"2020","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.breast.2026.104848_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104848_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104848_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2022.07.001","article-title":"HER2-low inflammatory breast cancer: clinicopathologic features and prognostic implications","volume":"174","author":"Tarantino","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104848_bib18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-Low breast cancer among patients in the national cancer database","volume":"9","author":"Peiffer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104848_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000527391","article-title":"HER2-Low breast cancer: where are we?","volume":"17","author":"Molinelli","year":"2022","journal-title":"Breast Care"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:28:24Z","timestamp":1784928504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S096097762600158X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104848","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104848"}}